Leaflet SMECTA 3g/sachet powder for oral suspension

Indicated for: diarrhea

Route of administration: oral

Substance: diosmectitis (probiotic)

ATC: A07BC05 (Alimentary tract and metabolism | Intestinal adsorbents | Other intestinal adsorbents)

Diosmectite is a medication used for the treatment of acute and chronic diarrhea, as well as for relieving symptoms associated with gastrointestinal disorders, such as abdominal pain, bloating, and intestinal discomfort. It is an adsorbent agent that acts locally in the digestive tract.

Diosmectite has a lamellar structure and a high capacity to adsorb toxins, bacteria, and viruses in the intestine, thereby helping to protect the intestinal mucosa. It also forms a protective layer on the mucosal surface, reducing inflammation and irritation.

It is indicated for both adults and children, including infants, and is considered a safe treatment for diarrhea. In cases of acute diarrhea, diosmectite can be used alongside oral rehydration therapy to prevent dehydration.

Side effects are rare and usually mild. They may include constipation or allergic reactions, such as skin rashes. In general, diosmectite is well-tolerated and can be used short-term without significant risks.

Patients should strictly follow the doctor’s or package instructions regarding dosage. Adequate hydration is essential, especially in cases of acute diarrhea, to prevent complications caused by fluid and electrolyte loss.

SMECTA 3g/sachet powder for oral suspension MAYOLY PHARMA FRANCE, diosmectitis

General data about SMECTA 3g/sachet

  • Substance: diosmectitis
  • Date of latest medicines list: 01-07-2025
  • Product code: W71195002
  • Concentration: 3g
  • Pharmaceutical form: powder for oral suspension
  • Quantity: 10
  • Product type: Original
  • Prescription status: OTC - Over the Counter = medicine that does not require a medical prescription.

Marketing authorisation

  • Manufacturer: MAYOLY INDUSTRIE - FRANTA
  • Holder: MAYOLY PHARMA FRANCE - FRANTA
  • Number: 6706/2014/01
  • Shelf life: 3 years